To answer your question, there was a large joint clinical study by MD Andersons Cancer Center in Texas, Moffitt Cancer Center in Florida and Levine Cancer Institute in North Carolina to find out how the timing of BCG after TURBT will affects effective ness of BCG treatment.
Over 500 patients were involved, with a median (range) of 26 (6-188) days from TURBT, their studies showed the following conclusion.
The rates of tolerability and response to adequate BCG are not predicated by the timing of induction BCG instillation after TURBT. Early administration in properly selected patients is safe and delays do not affect therapeutic response. So, I would not worry much yet.
The study on timing of BCG after TURBT
pubmed.ncbi.nlm.nih.gov/33783950/
As Alan mentioned, if the delay persists without knowing when you have have BCG treatment, one option is to participate on the clinical trial on the clinical trial BRIDGE which is to compare Gemcitabine + Docetaxel intravesical chemotherapy vs BCG for BCG naïve patients.
Gemcitabine + Docetaxel protocol was developed by University of Iowa team under Dr. Michael O'Donnell, who is known as one of early Guru for non muscle bladder cancer along with Dr. Donald Lamm of University of Arizona, now retired. Gemcitabine + Docetaxel protocol was used for those patient who did not respond to BCG, but during BCG shortage, it was used also BCG naïve patients with very good result. I think this trial is good trial for patients because patient will receive either GEM/ODC treatment or BCG treatment.
Link to the clinical trial information
www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-04864&r=1
best
